Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$2.67 +3.9%	$2.50	$1.60 ▼ $17.55	$72.28M	1.65	407,995 shs	42,760 shs
CRDF Cardiff Oncology	$4.46 +8.1%	$3.36	$2.01 ▼ $5.64	$296.37M	1.52	1.18 million shs	1.44 million shs
IMMP Prima BioMed	$1.65 +0.9%	$1.79	$1.32 ▼ $2.72	$240.23M	1.71	159,652 shs	69,154 shs
SGMT Sagimet Biosciences	$9.52 +0.4%	$6.05	$1.73 ▼ $10.43	$292.12M	3.35	1.09 million shs	397,209 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-4.62%	+3.20%	+6.83%	+15.18%	-82.21%
CRDF Cardiff Oncology	-0.24%	+4.57%	+8.14%	+46.62%	+64.14%
IMMP Prima BioMed	-3.55%	-4.12%	-6.32%	+12.41%	-20.10%
SGMT Sagimet Biosciences	+0.32%	+3.72%	+14.75%	+369.80%	+179.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	2.1394 of 5 stars	3.3	3.0	0.0	0.0	1.3
CRDF Cardiff Oncology	1.2288 of 5 stars	3.4	0.0	2.0	0.0	0.6
IMMP Prima BioMed	1.5025 of 5 stars	3.5	1.0	3.3	0.0	0.0
SGMT Sagimet Biosciences	2.816 of 5 stars	3.5	3.0	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	218.35% Upside
CRDF Cardiff Oncology	2.83	Moderate Buy	$11.70	162.63% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	325.53% Upside
SGMT Sagimet Biosciences	3.00	Buy	$26.60	179.29% Upside

Current Analyst Ratings Breakdown

Latest ANRO, SGMT, IMMP, and CRDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.62 per share	N/A
CRDF Cardiff Oncology	$587K	504.89	N/A	N/A	$1.86 per share	2.40
IMMP Prima BioMed	N/A	N/A	N/A	N/A	$1.05 per share	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$61.43M	-$2.34	N/A	N/A	N/A	N/A	-39.35%	-33.86%	8/12/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.76	N/A	N/A	N/A	N/A	-35.21%	-34.09%	8/13/2025 (Estimated)

Latest ANRO, SGMT, IMMP, and CRDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SGMT Sagimet Biosciences	-$0.57	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/8/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	-$0.56	+$0.23	-$0.56	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.15	22.53	22.53
CRDF Cardiff Oncology	N/A	6.22	6.22
IMMP Prima BioMed	N/A	18.86	N/A
SGMT Sagimet Biosciences	N/A	20.34	20.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CRDF Cardiff Oncology	16.29%
IMMP Prima BioMed	2.32%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	N/A
CRDF Cardiff Oncology	7.70%
IMMP Prima BioMed	3.07%
SGMT Sagimet Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
SGMT Sagimet Biosciences	8	30.68 million	26.17 million	Optionable

ANRO, SGMT, IMMP, and CRDF Headlines

Recent News About These Companies

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by Analysts

July 1, 2025 | marketbeat.com

SGMT Sagimet Biosciences Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Sagimet Biosciences Inc News (SGMT) - Investing.com

June 27, 2025 | investing.com

Sagimet Biosciences Inc. (SGMT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Sagimet Biosciences Inc.

June 14, 2025 | wsj.com

Sagimet Biosciences updates executive compensation

June 12, 2025 | investing.com

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

June 11, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...

June 11, 2025 | morningstar.comM

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know

June 9, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

June 9, 2025 | globenewswire.com

Sagimet Biosciences Analyst Ratings

June 5, 2025 | benzinga.com

Sagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment

June 4, 2025 | marketwatch.com

Sagimet Biosciences shares soar on positive acne treatment trial results

June 4, 2025 | ca.investing.com

Sagimet partner Ascletis announces significant Phase III acne data

June 4, 2025 | thepharmaletter.comT

Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results

June 4, 2025 | msn.com

Sagimet climbs as acne therapy hits main goals in late-stage trial in China

June 4, 2025 | msn.com

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

June 4, 2025 | aol.comA

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

June 4, 2025 | seekingalpha.com

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

June 4, 2025 | globenewswire.com

Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment

May 24, 2025 | investing.com

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction ...

May 24, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, SGMT, IMMP, and CRDF Company Descriptions

Alto Neuroscience NYSE:ANRO

$2.67 +0.10 (+3.89%)

As of 03:49 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Cardiff Oncology NASDAQ:CRDF

$4.46 +0.34 (+8.13%)

As of 03:49 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Prima BioMed NASDAQ:IMMP

$1.64 +0.02 (+0.92%)

As of 03:48 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Sagimet Biosciences NASDAQ:SGMT

$9.52 +0.03 (+0.36%)

As of 03:49 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time